Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
CytoDyn Inc CYDY
(Total Views: 713)
Posted On: 10/04/2020 8:01:40 PM
Post# of 155739
Posted By: MD VIROLOGIST
Re: viridi #59699
From "up to date":

Patients with severe disease who are receiving supplemental oxygen – For patients on supplemental oxygen (including those who are on high-flow oxygen and noninvasive ventilation), we suggest low-dose dexamethasone. Trial data suggest that dexamethasone improves mortality in patients who are on noninvasive oxygen supplementation; it is uncertain if there are particular patients in this relatively heterogeneous group who would benefit more than others.

For patients who are on low-flow supplemental oxygen only, we also suggest remdesivir. Subgroup analysis of trial data suggests that remdesivir improves mortality in patients who are on low-flow supplemental oxygen, but clinical benefit is less certain in patients who need higher levels of noninvasive support (eg, high-flow oxygenation and noninvasive ventilation). We also suggest remdesivir in patients with higher levels of noninvasive support, but prioritize it for patients on low-flow supplemental oxygen.

Of course I am not sure if this applies to POTUS, unless I had the opportunity to see his chart.













(0)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site